Bak - Network of Cancer Research

Navitoclax (ABT-263) is an Orally Active Bcl-2 Inhibitor for Chronic Lymphocytic Leukemia Research

Louis Gilman March 6, 2023

Bcl-2 family proteins, known as B-cell lymphoma 2, are regulators of programmed cell death. Additionally, the bcl-2 family includes pro-apoptotic and anti-apoptotic proteins. Anti-apoptotic proteins refer to Bcl-2, Bcl-x (L),…

Cancer

MSN-125 is a Potent Bax and Bak Oligomerization Inhibitor

Louis Gilman March 7, 2020

Aberrant apoptosis can lead to acute or chronic degenerative diseases. Apoptosis largely divides into two pathways ultimately leading to caspase activation and subsequent cellular disintegration. Extracellular signals activating death receptors…

Navitoclax (ABT-263) is an Orally Active Bcl-2 Inhibitor for Chronic Lymphocytic Leukemia Research

MSN-125 is a Potent Bax and Bak Oligomerization Inhibitor

You Missed

BI 7446 is a STING Agonist for Immuno-oncology Research

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research